Current German DRG (diagnosis related groups) system "threatens innovation"
This article was originally published in Clinica
Germany's new diagnosis related groups (DRG) system for hospital reimbursement is threatening the adoption of innovative medical technology into the health service because it focuses too heavily on financial costs, claims Bernhard Rochell, DRG expert at the federal doctors' chamber (BAK). Speaking last week in Berlin, he said that at present it appeared that hospitals and sickness funds were "pulling at opposite ends of the same rope". He advised: "For new procedures we need qualitative arguments, especially where costs are seen to rise."
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.